Finally, a placebo-controlled trial revealed that an oral dose of 500 mg/tablet of curcumin–phospholipid supplementation (Meriva®) taken twice daily decreased plasma pro-inflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1), IFN-γ and IL-4, and lipid peroxidation by modulating gut microbiota composition through a reduction in the bacterial community of Enterobacter and Escherichia-Shigella, and a significant increase in the relative abundance of Lachnoclostridium, Lactobacillaceae and Prevotellaceae after 6 months in subjects with chronic kidney disease [224]. This evidence concerns the gene CCL2 and chronic kidney disease.